|
SARS-CoV-2 Neutralizing Human Monoclonal Antibodies
Application
Monoclonal antibodies to SARS-CoV2 for use in COVID-19 diagnostics and therapeutics.
Key Benefits
Demonstrably neutralizing, important for therapeutic mAbs.
Most bind both RBG and stalk portion of spike protein, useful in case SARS-CoV2 strains develop variation in RBD.
Market Summary
Coronavirus (COVID-19) is an infectious...
Published: 4/23/2024
Contributor(s): Jens Wrammert, Carl Davis, Mehul Suthar, Robert Kauffman
|
|
Serological Test for SARS-CoV-2
Application
Clinical assay for detecting SARS-CoV-2 neutralizing antibodies.
Key Benefits
Highly specific and sensitive.
Fewer false positives than commercially available tests.
Market Summary
SARS-CoV-2 is currently causing a devastating pandemic and there is a pressing need to understand the dynamics, specificity, and neutralizing...
Published: 12/20/2023
Contributor(s): Rafi Ahmed, Mehul Suthar, John Roback, Jens Wrammert, Robert Kauffman
|
|
Antibodies for Zika and Dengue Viruses
Applications
ELISA
Western Blot
Immunohistochemistry
Specificity
Human monoclonal
Technical Summary
Zika Virus (ZIKV) is a mosquito borne filovirus responsible for a 2016-2017 epidemic in North and South America. ZIKV nonstructural protein 1 (NS1) is a pathogenicity factor implicated in virus replication, host interaction and immune invasion....
Published: 4/23/2024
Contributor(s): Jens Wrammert, Mark Mulligan
|
|
Cross-Reactive Antibodies Against Influenza Virus
Application
Human recombinant antibodies against influenza, including H1N1, for the development of diagnostic tests and universal flu vaccines.
Key Benefits
Broadly protective antibodies against multiple influenza strains
Market Summary
Influenza spreads swiftly and globally, causing some of the most severe pandemics in the last century. Each year,...
Published: 7/28/2023
Contributor(s): Rafi Ahmed, Patrick Wilson, Jens Wrammert
|